Photographs of rabbits in the alert resting position were used to record head position. Semicircular canals were surgically exposed and points measured along each canal were used to compute the best-fit plane using a least-squares method. Computations of mean best-fit planes showed that the horizontal canals were not carried horizontally in the rabbit. The anteromedial edges were superior by 16 degrees. The anterior canals were vertically oriented and made an angle of 43 degrees to the sagittal plane. The posterior canal was tipped in the anterior direction slightly and also made an acute angle (26 degrees) with the frontal plane. Rabbit semicircular canals deviated significantly from orthogonality. The range was 86 degrees (anterior canals) to 133 degrees (posterior canals). Thus, there were no co-planar canals. Such semicircular canal geometry has implications for the neural circuitry controlling posture in the rabbit.
Objective: To compare the outcome of patients undergoing autologous peripheral blood stem cell transplantation (PBSCT) conditioned with FluBuTBI or BEAM (BCNU, Etoposide, Cytarabine, and Melphalan) at our institution. Patients and Methods: We conducted a retrospective analysis of patients (n¼101) who underwent autologous PBSCT at our institution and were conditioned with BEAM (n¼63) or FluBuTBI (n¼38) between January 2006 and December 2012. Recipients were classified according to CIBMTR criteria and those conditioned with BEAM were low risk (n¼17) and intermediate risk (n¼46). Recipients conditioned with FluBuTBI were low risk (n¼9), intermediate risk (n¼25), and high risk (n¼4). Median age of patients in the BEAM group was 52.3 years compared to 59.6 years for FluBuTBI. At the time of transplantation, 38 of 63 patients who received BEAM were in complete remission (60%) compared to 19 of 38 patients (50%) for FluBuTBI. Median time of follow up was 57 months for BEAM and 24 months for FluBuTBI. FluBuTBI consisted of intravenous (IV) Fludarabine 50 mg/ m 2 /day infused over 1 hour on days-6 through-2, IV Busulfan 3.2 mg/kg/day on days-5 through-2 (infusion rate 80 mg/kg/hour) and TBI 200 cGy on days-2 and-1. BEAM regimen consisted of IV BCNU 300 mg/m 2 infused over 1 hr on day-5, Etoposide 200 mg/m 2 /day over 3 hours on days-5 through-2, Cytarabine 200 mg/m 2 /day over 1 hour every 12 hours on days-5 through-2, and Melphalan 140 mg/m 2 over 1 hr on day-1. Diagnoses were Hodgkin's lymphoma (n¼26), B-cell lymphoma NOS (n¼3), anaplastic large cell lymphoma (n¼2), Burkitt's lymphoma (n¼3), diffuse large B-cell lymphoma (n¼ 23), follicular lymphoma (n¼16), mantle cell lymphoma (n¼22), peripheral T-cell lymphoma (n¼5), transformed follicular lymphoma (n¼1). Results: Overall survival at 3 years for patients undergoing BEAM was 71% and for FluBuTBI 72%. Cumulative incidence of disease progression or relapse at 3 years for BEAM was 39% compared to 32% for the FluBuTBI group. Treatment related mortality was 3% (n¼2) in the BEAM group and 0% in the FluBuTBI group. Treatment related MDS/AML occurred in 6% (n¼4) in the BEAM group compared to 2% (n¼1) in the Flu-BuTBI group. Grade 3-4 mucositis was seen in 16% (n¼6) in the FluBuTBI group compared to 4% (n¼3) in the BEAM group. Conclusion: Comparison of the two groups showed identical overall survival at 3 years, but a trend to reduced relapse, treatment related mortality and secondary MDS/AML, in patients conditioned with FluBuTBI. This difference was present despite older and higher risk patients in the FluBuTBI group. Mucositis was more frequent in the FluBuTBI group. Conditioning with FluBuTBI is a safe and effective alternative to BEAM for autologous PBSCT that offers the potential for further optimization by study of Busulfan pharmacokinetics and the introduction of targeted radiation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.